!! History Commons Alert, Exciting News

Profile: Amgen

Amgen was a participant or observer in the following events:

Concerned about Democratic plans (see After November 7, 2006) to push for lower drug prices and tighter regulation of the pharmaceutical industry, drug companies begin communicating with Democrats and recruiting lobbyists with Democratic connections. [New York Times, 11/24/2006]
bullet Billy Tauzin, president of the drug lobbying organization Pharmaceutical Research and Manufacturers of America (PRMA), meets with Senator Byron L. Dorgan, a North Dakota Democrat who has spent six years pushing for legislation that would allow drug imports from Canada. [New York Times, 11/24/2006]
bullet Amgen, a biotechnology firm, retains George C. Crawford, a former chief of staff for Representative Nancy Pelosi (D-Ca), as a lobbyist. [New York Times, 11/24/2006]
bullet Merck hires Peter Rubin, a former aide to Representative Jim McDermott of Washington. [New York Times, 11/24/2006]
bullet Cephalon contracts Kim Zimmerman, a health policy aide to Senator Ben Nelson (D-Ne). [New York Times, 11/24/2006]
bullet The Biotechnology Industry Organization retains Paul T. Kim, a former aide to Senator Edward M. Kennedy (D-Ma) and Representative Henry A. Waxman (D-Ca). [New York Times, 11/24/2006]
bullet One unnamed medicare expert who works for House Democrats tells the New York Times in late November that he received three separate job offers in one day from the drug industry. [New York Times, 11/24/2006]

Entity Tags: Kim Zimmerman, Paul T. Kim, W.J. (“Billy”) Tauzin, Peter Rubin, Merck, Biotechnology Industry Organization, Amgen, Byron L. Dorgan, George C. Crawford, Cephalon

Timeline Tags: US Health Care

At a Pharmaceutical Research and Manufacturers of America (PRMA) board meeting, top executives from two dozen drug companies meet to work on a strategy to prevent the incoming Democratically-controlled Congress from passing legislation that would lower drug prices and tighten regulation of the industry (see After November 7, 2006). Their top concern is a bill they expect Democrats to push that would allow the government to negotiate lower drug prices for millions of older Americans on Medicare. Lobbyists for the industry concede that it is probable that such legislation will be passed by the House. But they say they are determined to have it killed in the Senate. If their efforts fail, and the Senate does pass such a bill, the drug industry believes that President Bush would veto it and that the veto would be upheld by the remaining Republicans in the Senate. Among those attending the meeting are Kevin Sharer, chairman of Amgen; Jeffrey B. Kindler, chief executive of Pfizer; Sidney Taurel, chairman of Eli Lilly; and Richard T. Clark, chief executive of Merck. [New York Times, 11/24/2006]

Entity Tags: Eli Lilly, Pfizer, Pharmaceutical Research and Manufacturers of America, Amgen, Sidney Taurel, W.J. (“Billy”) Tauzin, Jeffrey B. Kindler, Kevin Sharer, Richard T. Clark, Merck

Timeline Tags: US Health Care

Ordering 

Time period


Email Updates

Receive weekly email updates summarizing what contributors have added to the History Commons database

 
Donate

Developing and maintaining this site is very labor intensive. If you find it useful, please give us a hand and donate what you can.
Donate Now

Volunteer

If you would like to help us with this effort, please contact us. We need help with programming (Java, JDO, mysql, and xml), design, networking, and publicity. If you want to contribute information to this site, click the register link at the top of the page, and start contributing.
Contact Us

Creative Commons License Except where otherwise noted, the textual content of each timeline is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike